Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Intensive Case Management for Substance Use Disorders (RCT) (ICM)

13 novembre 2026 mis à jour par: Psychiatric Services Aargau AG

Intensive Case Management for Patients With Substance Use Disorders and Complex Psychosocial Needs: A Randomized Controlled Trial

This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.

Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).

Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.

In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:

  • People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
  • people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
  • patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
  • people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.

Sex and gender will be treated as potential covariates and will be considered in the analysis.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

180

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Canton of Aargau
      • Windisch, Canton of Aargau, Suisse, 5210
        • Recrutement
        • PDAG
        • Contact:
        • Chercheur principal:
          • Johannes Senesi, Msc

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 64 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • 4 or more inpatient admissions in the last 24 months
  • Diangosed SUD
  • Residence or temporary stay in the canton of Aargau

Exclusion Criteria:

  • any emergency situation requiring psychiatric or hospital admissions
  • inability to give informed consent
  • acute, unstable psychotic symptoms
  • acute risk of harm to self or others
  • insufficient german language skills

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Recherche sur les services de santé
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Experimental

receives ICM immediately

Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement:

  1. Intensive crisis intervention: Offering immediate, flexible support in acute crises, preventing escalations early and strengthening the stability of patients.
  2. Relationship continuity: Establishing an empathetic & constant presence, breaking down barriers, creating a trustful, stable relationship.
Comparateur actif: Waiting List

Same as Experimental, only with 6-Month TAU-Waiting List before ICM

TAU will take place for 6 months before starting with ICM

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Inpatient Admissions (Health Service utilisation)
Délai: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Number of Inpatient Days (Health Service utilisation)
Délai: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
WHOQoL-BREF
Délai: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Quality of Life

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
SFQ
Délai: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Social Functioning Questionnaire

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
ASSIST
Délai: 6 Months (exploratory), 24 months (exploratory)

Substance use characteristics

6 Months (exploratory), 24 months (exploratory)
Continuity of Care (Brice-Boxerman)
Délai: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Continuity of Care describes timeframes of the health services used outside the ward.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Linking
Délai: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Retention
Délai: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Retention describes the voluntary staying of patients in the ICM treatment

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
BSCL
Délai: 6 Months (exploratory), 24 months (exploratory)

Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care

6 Months (exploratory), 24 months (exploratory)
EQ-5D-5L
Délai: 6 Months (exploratory), 24 months (exploratory)

EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER)

6 Months (exploratory), 24 months (exploratory)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

4 juillet 2026

Achèvement primaire (Estimé)

1 juillet 2029

Achèvement de l'étude (Estimé)

1 juillet 2029

Dates d'inscription aux études

Première soumission

13 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • PDAG-ICM
  • HumRes68440 (Autre identifiant: Human Research Switzerland (HumRes))

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner